Business Context and Reporting Period
This Form 8-K Current Report for Assembly Biosciences, Inc. (ASMB) covers events occurring on December 1, 2023, and December 7, 2023. The filing reports a change in corporate headquarters and a new appointment to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and administrative changes rather than financial performance.
Material Changes
- Board Appointment: On December 7, 2023, the Board appointed Tomas Cihlar, Ph.D., as a new director. Dr. Cihlar is a designee of Gilead Sciences, Inc., serving as Gilead's Senior Vice President, Virology. This appointment fulfills obligations under an Investor Rights Agreement dated October 15, 2023. Dr. Cihlar will serve without compensation.
- Headquarters Relocation: Effective December 1, 2023, the Company moved its corporate headquarters to Two Tower Place, 7th Floor, South San Francisco, California 94080. The Company's telephone number is (833) 509-4583.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, specific risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the terms of the Investor Rights Agreement with Gilead Sciences, Inc. signed on October 15, 2023, to understand the scope of Gilead's influence on the Board.
- Confirm the operational impact of the headquarters relocation to Two Tower Place.
- Review the Company's most recent 10-K or 10-Q filings for current financial metrics, as this 8-K does not contain financial data.